Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor

El, McMichael; Nb, Courtney; Mc, Duggan; Wesolowski, Robert; Quiroga, Dionisia; Sv, Kondadasula; Ls, Atwal; Bhave, Neela; Luedke, Eric; Ac, Jaime-Ramirez; Ar, Campbell; Mo, Xiaokui; Byrd, J. C.; Carson, William E.

doi:10.1080/2162402x.2017.1312045

Cited by 3 publications

(1 citation statement)

References 50 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the interaction between Fc region and FcRs simultaneously opsonize the target cells for antibody-dependent cell-mediated cytotoxicity (ADCC) since NK cells are the crucial mediators of this reaction in vivo ( 87 , 97 ). Moreover, FcR-activated NK cells can also secrete IFN-γ, TNF-α, and lead to increased expression of interleukin-21 receptor that suppress tumor growth ( 98 , 99 ). Therefore, insights raise intriguing questions as to whether anti-tumor effects induced by CD47-antibodies occur through Fc-dependent mechanisms?…”

Section: Targeting Cd47 For Cancer Immunotherapymentioning

confidence: 99%

CD47 as a promising therapeutic target in oncology

Zhao

Song

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

CD47 is ubiquitously expressed on the surface of cells and plays a critical role in self-recognition. By interacting with SIRPα, TSP-1 and integrins, CD47 modulates cellular phagocytosis by macrophages, determines life span of individual erythrocytes, regulates activation of immune cells, and manipulates synaptic pruning during neuronal development. As such, CD47 has recently be regarded as one of novel innate checkpoint receptor targets for cancer immunotherapy. In this review, we will discuss increasing awareness about the diverse functions of CD47 and its role in immune system homeostasis. Then, we will discuss its potential therapeutic roles against cancer and outlines, the possible future research directions of CD47- based therapeutics against cancer.

show abstract